GBS INC (GBS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:GBS • US36151G1058

0.4732 USD
0 (-0.04%)
At close: Oct 26, 2022
0.48 USD
+0.01 (+1.44%)
After Hours: 10/26/2022, 8:00:00 PM
Fundamental Rating

2

GBS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. While GBS seems to be doing ok healthwise, there are quite some concerns on its profitability. GBS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year GBS has reported negative net income.
  • In the past year GBS has reported a negative cash flow from operations.
GBS Yearly Net Income VS EBIT VS OCF VS FCFGBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA -67.24%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GBS Yearly ROA, ROE, ROICGBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 500 1K 1.5K 2K 2.5K

1.3 Margins

Industry RankSector Rank
OM -1907.1%
PM (TTM) -1900.05%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBS Yearly Profit, Operating, Gross MarginsGBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, GBS has more shares outstanding
  • There is no outstanding debt for GBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GBS Yearly Shares OutstandingGBS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 5M 10M
GBS Yearly Total Debt VS Total AssetsGBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

  • GBS has an Altman-Z score of -4.38. This is a bad value and indicates that GBS is not financially healthy and even has some risk of bankruptcy.
  • GBS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.38
ROIC/WACCN/A
WACCN/A
GBS Yearly LT Debt VS Equity VS FCFGBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • GBS has a Current Ratio of 2.33. This indicates that GBS is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 2.33 indicates that GBS has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.33
GBS Yearly Current Assets VS Current LiabilitesGBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

  • GBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.84%, which is quite good.
  • The Revenue for GBS has decreased by -77.90% in the past year. This is quite bad
EPS 1Y (TTM)17.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.11%
Revenue 1Y (TTM)-77.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.84%

3.2 Future

  • Based on estimates for the next years, GBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.02% on average per year.
  • Based on estimates for the next years, GBS will show a very strong growth in Revenue. The Revenue will grow by 160.02% on average per year.
EPS Next Y44.09%
EPS Next 2Y35.56%
EPS Next 3Y20.24%
EPS Next 5Y12.02%
Revenue Next Year-100%
Revenue Next 2Y547.11%
Revenue Next 3Y251.78%
Revenue Next 5Y160.02%

3.3 Evolution

GBS Yearly Revenue VS EstimatesGBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2024 2025 2026 5M 10M 15M
GBS Yearly EPS VS EstimatesGBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • GBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year GBS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBS Price Earnings VS Forward Price EarningsGBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GBS Per share dataGBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • GBS's earnings are expected to grow with 20.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.56%
EPS Next 3Y20.24%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for GBS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GBS INC

NASDAQ:GBS (10/26/2022, 8:00:00 PM)

After market: 0.48 +0.01 (+1.44%)

0.4732

0 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-31
Earnings (Next)11-10
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.15%
Ins Owner Change0%
Market Cap7.05M
Revenue(TTM)437.15K
Net Income(TTM)-8.31M
Analysts0
Price Target4.59 (869.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.12
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.03
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.24%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1907.1%
PM (TTM) -1900.05%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.33
Altman-Z -4.38
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.11%
EPS Next Y44.09%
EPS Next 2Y35.56%
EPS Next 3Y20.24%
EPS Next 5Y12.02%
Revenue 1Y (TTM)-77.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.84%
Revenue Next Year-100%
Revenue Next 2Y547.11%
Revenue Next 3Y251.78%
Revenue Next 5Y160.02%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.27%
OCF growth 3YN/A
OCF growth 5YN/A

GBS INC / GBS FAQ

What is the fundamental rating for GBS stock?

ChartMill assigns a fundamental rating of 2 / 10 to GBS.


Can you provide the valuation status for GBS INC?

ChartMill assigns a valuation rating of 2 / 10 to GBS INC (GBS). This can be considered as Overvalued.


What is the profitability of GBS stock?

GBS INC (GBS) has a profitability rating of 0 / 10.